HMPL A251
Alternative Names: HMPL-A251Latest Information Update: 23 Dec 2025
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 16 Dec 2025 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA, China (IV, Infusion) (NCT07228247)
- 07 Nov 2025 HMPL A251 is available for licensing as of 03 Nov 2025. https://www.hutch-med.com/pipeline-and-products/our-pipeline/
- 23 Oct 2025 HUTCHMED plans phase-I/II trial for Solid tumours (Late-stage disease, Metastatic, Monotherapy, Unresectable/Inoperable, Second-line therapy or greater) in USA and China (IV, infusion) in December 2025 (NCT07228247)